Published in Proc Natl Acad Sci U S A on September 23, 2008
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol Ther Nucleic Acids (2013) 1.45
Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med (2012) 1.15
Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci U S A (2011) 0.98
Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization. Nat Biotechnol (2010) 0.97
Development of a novel mammalian cell surface antibody display platform. MAbs (2010) 0.94
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012. MAbs (2013) 0.93
Mining human antibody repertoires. MAbs (2010) 0.92
Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J (2009) 0.90
Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS One (2009) 0.88
Direct expression and validation of phage-selected peptide variants in mammalian cells. J Biol Chem (2013) 0.88
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria. Nat Commun (2015) 0.87
Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel) (2011) 0.86
A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format. PLoS One (2015) 0.83
In vitro Fab display: a cell-free system for IgG discovery. Protein Eng Des Sel (2014) 0.82
Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor. Cell Mol Immunol (2011) 0.81
Specific in vivo knockdown of protein function by intrabodies. MAbs (2015) 0.80
The B7-1 cytoplasmic tail enhances intracellular transport and mammalian cell surface display of chimeric proteins in the absence of a linear ER export motif. PLoS One (2013) 0.79
Applications of Yeast Surface Display for Protein Engineering. Methods Mol Biol (2015) 0.79
Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. MAbs (2016) 0.77
Simultaneous expression of displayed and secreted antibodies for antibody screen. PLoS One (2013) 0.77
High-Throughput Screening in Protein Engineering: Recent Advances and Future Perspectives. Int J Mol Sci (2015) 0.76
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma. MAbs (2014) 0.75
Cystatin F is a biomarker of prion pathogenesis in mice. PLoS One (2017) 0.75
In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid Libraries. J Immunol Res (2015) 0.75
Biologics to treat substance use disorders: Current status and new directions. Hum Vaccin Immunother (2016) 0.75
An immunological approach of sperm sexing and different methods for identification of X- and Y-chromosome bearing sperm. Vet World (2017) 0.75
Peptides and peptidomimetics as regulators of protein-protein interactions. Curr Opin Struct Biol (2017) 0.75
Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron (2004) 7.48
Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol (1997) 6.88
Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods (1985) 6.11
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A (1991) 5.94
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Reshaping human antibodies for therapy. Nature (1988) 4.82
In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A (1997) 4.71
Making antibody fragments using phage display libraries. Nature (1991) 4.61
Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 4.51
Monoclonal antibody successes in the clinic. Nat Biotechnol (2005) 4.43
Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol (1993) 4.19
Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol (2007) 3.56
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol (1992) 2.44
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol (2006) 2.05
Human antibodies from transgenic animals. Nat Biotechnol (2005) 2.04
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet (1997) 1.67
Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration (2002) 1.66
Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res (1997) 1.56
A high-throughput alphavirus-based expression cloning system for mammalian cells. Nat Biotechnol (2001) 1.55
Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos (2005) 1.47
Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng Des Sel (2007) 1.46
Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood (1983) 1.39
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J Immunol Methods (2003) 1.27
Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol (1997) 1.17
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Protein displays of the human immunoglobulin heavy, kappa and lambda variable and joining regions. Exp Clin Immunogenet (1999) 1.07
High-throughput generation and engineering of recombinant human antibodies. J Immunol Methods (2001) 1.05
Single, antigen-specific B cells used to generate Fab fragments using CD40-mediated amplification or direct PCR cloning. Biotechniques (1995) 1.03
Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav (2001) 0.92
High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study. Scand J Immunol (1997) 0.89
High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol (2004) 0.87
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol (2005) 3.14
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol (2007) 1.95
The coming of age of virus-like particle vaccines. Biol Chem (2008) 1.85
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity (2008) 1.34
Structural characterization of TSC-36/Flik: analysis of two charge isoforms. J Biol Chem (2003) 1.33
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A (2011) 1.33
Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol (2010) 1.32
Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochem J (2003) 1.31
Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol (2008) 1.30
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
Characterization of SMOC-1, a novel modular calcium-binding protein in basement membranes. J Biol Chem (2002) 1.23
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
Pseudoachondroplasia is caused through both intra- and extracellular pathogenic pathways. J Clin Invest (2002) 1.20
How adeno-associated virus Rep78 protein arrests cells completely in S phase. Proc Natl Acad Sci U S A (2005) 1.15
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol (2010) 1.11
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol (2006) 1.11
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 1.10
SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem (2003) 1.09
Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol (2012) 1.09
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol (2003) 1.09
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol (2008) 1.07
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol (2009) 1.05
Characterization of recombinant amino-terminal NC4 domain of human collagen IX: interaction with glycosaminoglycans and cartilage oligomeric matrix protein. J Biol Chem (2004) 1.05
Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine (2010) 1.05
Dendrimers Based on [1,3,5]-Triazines. J Polym Sci A Polym Chem (2006) 1.04
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med (2005) 1.04
Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med (2007) 1.03
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J Immunol (2010) 1.01
Vaccination against GIP for the treatment of obesity. PLoS One (2008) 1.01
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol (2005) 1.01
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur J Immunol (2002) 1.00
Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines (2008) 0.99
Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol (2009) 0.98
Alternative splicing of vasohibin-1 generates an inhibitor of endothelial cell proliferation, migration, and capillary tube formation. Arterioscler Thromb Vasc Biol (2008) 0.98
Osteopontin is not required for the development of Th1 responses and viral immunity. J Immunol (2005) 0.96
Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine (2010) 0.94
Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry. BMC Res Notes (2008) 0.94
Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol (2010) 0.94
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 0.94